PRODUCT INFORMATION



BFH772

Item No. 21386

CAS Registry No.: Formal Name:	890128-81-1 6-[[6-(hydroxymethyl)- 4-pyrimidinyl]oxy]-N-[3- (trifluoromethyl)phenyl]-1- naphthalenecarboxamide	
MF:	$C_{23}H_{16}F_{3}N_{3}O_{3}$	
FW:	439.4	
Purity:	≥95%	
UV/Vis.:	λ_{max} : 227 nm	
Supplied as:	A crystalline solid	\sim \sim \sim \sim \sim
Storage:	-20°C	
Stability:	≥4 years	
Information memory to the medication of the provided and the second descent and the second seco		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BFH772 is supplied as a crystalline solid. A stock solution may be made by dissolving the BFH772 in the solvent of choice, which should be purged with an inert gas. BFH772 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BFH772 in these solvents is approximately 30 mg/ml.

BFH772 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BFH772 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BFH772 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BFH772 is an inhibitor of VEGF receptor 2 (VEGFR2; IC₅₀ = 0.0027 μ M for the human receptor).¹ It is selective for human VEGFR2 over mouse VEGFR2 and human VEGFR1 and VEGFR3 (IC₅₀s = 1.5, 1.7, and 1.1 μ M, respectively), as well as 40-fold selective over B-RAF, RET, and Tie2. BFH772 inhibits VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC₅₀ = <0.01 nM). It inhibits VEGF-induced increases in tissue weight and Tie2 levels in an angiogenesis chamber implant model in mice when administered at doses of 1 and 3 mg/kg per day. BFH772 (3 mg/kg per day) inhibits primary tumor and metastasis growth in a B16 melanoma mouse model.

Reference

1. Bold, G., Schnell, C., Furet, P., et al. A novel potent oral series of VEGFR2 inhibitors abrogate tumor growth by inhibiting angiogenesis. J. Med. Chem. 59(1), 132-146 (2016).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM